# US 2017/0253655 A1 · Low dose immune checkpoint blockade in metastatic cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253655 A1
- Document ID: US20170253655A1
- Status: Published application
- Kind: A1
- Application number: 15/443,589
- Filed: 2017-02-27
- Published: 2017-09-07
- Earliest claimed: 2016-03-01
- Assignees: LODOCO CLINICAL Kft.
- Applicants: LODOCO CLINICAL Kft.
- Inventors: Tibor Bakács; Ralf Kleef
- Web page: https://patentgrep.com/patent/US20170253655A1

## CPC

- C07K 16/2818: {against CD28 or CD152}
- A61K 31/549: having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
- A61K 31/664: Amides of phosphorus acids
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 38/2013: {IL-2}
- A61K 39/0008: {Antigens related to auto-immune diseases; Preparations to induce self-tolerance}
- A61K 39/00115: {Apoptosis related proteins, e.g. survivin or livin}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- C07K 16/30: from tumour cells
- A61K 2039/505: {comprising antibodies}
- A61K 2039/507: {Comprising a combination of two or more separate antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating cancer comprising and reducing autoimmune side effects in administration of anti-CTLA-4 antibodies. The invention provides methods for low dose immune checkpoint (IC) treatment of metastatic cancer by delivering anti-CTLA-4 and anti-PD-1 antibodies to cancer patients. Methods also provide for IL-2 stimulation for the activation of T cells against tumor cells. The invention further provides methods for daily cyclic high fever response (hyperthermia) during IL-2 therapy. The methods provide treatment of metastatic cancer without unacceptable autoimmune side effects.

## Claims

### Claim 1

A method for reducing autoimmune side effects by administering an effective amount of anti-PD-1 antibody to a patient anticipating or experiencing anti-CTLA-4 autoimmune side effects or by administering an effective amount of anti-CTLA-4 antibody to a patient anticipating or experiencing anti-PD-1 autoimmune side effects.

### Claim 2 (depends on 1)

The method of claim 1 for reducing autoimmune side effects in administration of anti-CTLA-4 antibodies by administering an effective amount of anti-PD-1 antibody to a patient anticipating or experiencing anti-CTLA-4 autoimmune side effects.

### Claim 3 (depends on 1)

The method of claim 1 for reducing autoimmune side effects in administration of anti-PD-1 antibodies by administering an effective amount of anti-CTLA-4 antibody to a patient anticipating or experiencing anti-PD-1 autoimmune side effects.

### Claim 4 (depends on 1)

The method of claim 1, further comprising administering Taurolidine to the patient, wherein the patient is being treated with HD IL-2.

### Claim 5 (depends on 1)

The method of claim 1, wherein the patient is being treated with hyperthermia.

### Claim 6 (depends on 1)

The method of claim 1, comprising administering to the patient in need 0.5 mg/kg or lower dose of anti-PD-1 antibody with co-administration of 0.3 mg/kg or lower dose of anti-CTLA-4 antibody.

### Claim 7 (depends on 1)

The method of claim 1, comprising administering to the patient in need 300mg/m2 or lower dose of cyclophosphamide.

### Claim 8

A method for enhancing cancer immunity in a patient while reducing autoimmunity in said patient comprising administering anti-PD-1 antibody and anti-CTLA-4 antibody in effective amounts to a patient in need of treatment.

### Claim 9 (depends on 8)

The method of claim 8, further comprising administering Taurolidine to the patient, wherein the patient is being treated with HD IL-2.

### Claim 10 (depends on 8)

The method of claim 8, wherein the patient is being treated with hyperthermia.

### Claim 11 (depends on 8)

The method of claim 8, comprising administering to the patient in need 0.5 mg/kg or lower dose of anti-PD-1 antibody with co-administration of 0.3 mg/kg or lower dose of anti-CTLA-4 antibody.

### Claim 12 (depends on 8)

The method of claim 8, comprising administering to the patient in need 300mg/m2 or lower dose of cyclophosphamide.

### Claim 13 (depends on 8)

The method of claim 8, wherein the anti-PD-1 antibody and anti-CTLA-4 antibody are administered simultaneously.

### Claim 14 (depends on 8)

The method of claim 8, wherein the anti-PD-1 antibody and anti-CTLA-4 antibody are administered at different times.

### Claim 15 (depends on 8)

The method of claim 8 comprising administering to a patient in need anti-PD-1 antibody and anti-CTLA-4 antibody in amounts effective to produce an anti-cancer effect, wherein the administration of anti-PD-1 antibody and anti-CTLA-4 antibody results in a lower level of autoimmunity as compared to administration of either anti-CTLA-4 or anti-PD-1 antibody alone.

### Claim 16 (depends on 15)

The method of claim 15, wherein the anti-cancer effect is an effect chosen from decreased tumor burden, decreased metastasis, decreased tumor growth, and reduction in new tumor formation.

### Claim 17

A composition for treating cancer comprising effective amounts of anti-PD-1 antibody and anti-CTLA-4 antibody, and at least one pharmaceutically acceptable excipient, wherein the amount of the antibodies in the composition is sufficient to produce a lower level of autoimmunity as compared to a composition of either antibody alone.
